France's $19.4 Billion Biomanufacturing Surge | Continuous Bioprocessing, AI-Driven Innovation by CEA-Leti & Ondalys and Insights

Continuous Bioprocessing Market in France | The Future of Innovation, Investment, and Sector Growth

With the biopharmaceutical and pharmaceutical sectors racing ahead at a breakneck speed, one of the areas of considerable innovation and promise is continuous bioprocessing. This technology, instead of traditional batch processing, offers substantial gains in efficiency, cost savings, and scalability.

France, as a biomanufacturing power in Europe, is becoming a center in the development and adoption of continuous bioprocessing technologies.

France Bioproduction Congress 2025 | The Unifying Forum for Bioprocessing Innovation

The 9th France Bioproduction Congress, held on March 19-20, 2025, in Tours, France, assembled over 700 experts in the pharmaceutical and biopharmaceutical sectors. Polepharma and Medicen Paris Region's congress offered a top-level meeting space in which to unveil new trends in bioproduction and uninterrupted bioprocessing technologies.

You can get the Expert Analysis with the Free Sample Copy of the Continuous Bioprocessing Market Research Report: https://www.marketdigits.com/request/sample/4395

The congress featured thematic sessions on:

Current Trends, Challenges, and Opportunities: Addressing the evolving face of biomanufacturing.

Accelerating Bioproduction for Patient Benefit: Examining the need for faster, more efficient production.

The Age of AI Bioproduction Revolution: Investigating the potential of AI and automation to maximize biomanufacturing processes.

New Bioproduction Models for Future Biotherapies: Highlighting how new-generation bioprocessing models will facilitate new biotherapies, including gene therapies and monoclonal antibodies.

Among these conversations, the incorporation of continuous bioprocessing was identified as a main point of interest. Specialists presented information regarding the most recent technological developments and the significant influence of continuous bioprocessing on the efficiency of biomanufacturing.

Continuous Bioprocessing | The Pharmaceutical Manufacturing Revolution

Continuous bioprocessing is a new technique in biomanufacturing that greatly differs from traditional batch process. With batch production, raw material is loaded into the bioreactor, and the entire process is carried out before harvesting the final product.

With continuous bioprocessing, there is a constant flow of raw material and product, and throughput is improved, process time is reduced, and scalability is improved.

Several technological innovations are driving the adoption of continuous bioprocessing, including:

Real-time process monitoring: Methods such as Raman probes and chemometric modeling, presented by Ondalys at the congress, enable real-time monitoring and control of suspended cell cultures in bioreactors.

It forecasts based on machine learning algorithms critical process parameters and quality attributes, which is important to guarantee consistent product quality in continuous bioprocessing operations.

Integration with automation and AI: Artificial intelligence (AI) used in continuous bioprocessing systems allows automation of the process, predictive maintenance, and process control. This reduces errors, improves production timelines, and improves the scalability of the biomanufacturing process.

Next-generation cell culture technologies: CEA-Leti, a French world-class research institute, discussed improvements in large-scale AAV (adeno-associated virus) bioproduction, with focus on the integration of continuous processing with next-generation monitoring tools such as on-line cell counting and viability measurement.

These technologies are particularly applicable to the production of gene therapies and biologics.

These are not just technologies on paper-these have concrete uses that already are changing the landscape of biopharmaceutical manufacturing.

Market Expansion and Investment Prospects

The global market for continuous bioprocessing is increasing very rapidly, and France is expected to be at the center of this development. MarketsandMarkets pegged the market for bioprocessing at $12.9 billion in 2024 and estimated that it would grow to $19.4 billion in 2028 at a rate of 10.3% CAGR.

This part of the market will remain a key contributor to this trend as continuous bioprocessing becomes increasingly popular.

France, with its established biomanufacturing network, strong R&D and capabilities, and strategic industry collaborations, is an attractive investment location for continuous bioprocessing technologies. The French government, through the efforts of Medicen Paris Region and Polepharma, has been actively fostering innovation in biopharma.

Polepharma, for instance, has supported various research programs to improve the efficiency of bioprocessing, and France can be expected to see considerable investment in biomanufacturing plants over the next decade.

Get the complete view on 189 Pages Research Report on Continuous Bioprocessing Market: https://www.marketdigits.com/continuous-bioprocessing-market-1708610489

Principal Investment Areas:

Automation and AI in Bioprocessing: Investment in AI-based platforms for continuous bioprocessing is one of the drivers of growth. The platforms enable real-time process optimization and predictive analytics, which will become a crucial part of large-scale biomanufacturing during the next few years.

Ondalys and CEA-Leti are already at the forefront, providing investors with strong incentives to invest in the development and deployment of these new solutions.

Large-Scale Biomanufacturing Infrastructure: France's Île-de-France (Paris) and Lyon regions are well-placed to attract investment in biomanufacturing infrastructure. Increasing demand for biologics and cell and gene therapies generates a clear need for investment in sophisticated production facilities that can support continuous bioprocessing.

Regulatory and Quality Control Systems: The regulatory framework for continuous bioprocessing is advanced, but France's strong pharmaceutical regulatory framework, supported by institutions such as ANSM (National Agency for the Safety of Medicines and Health Products), enforces high-quality requirements on new biomanufacturing technology. Regulatory consulting, certification, and compliance firms will see fast growth with the adoption of continuous bioprocessing gaining momentum.

Advanced Quality Monitoring and Control Technologies: Real-time monitoring technologies like those offered by Ondalys that employ sensors and artificial intelligence to control the process in real-time will be highly sought after. These technologies improve product quality, reduce the cost, and increase efficiency in general. Hence, companies that develop such technologies will have great investment opportunities.

R&D expenditure and public-private partnerships:

In France, public-private collaborations are propelling ongoing bioprocessing innovation. CEA-Leti, a key biomanufacturing R&D partner, is, for example, collaborating with the industry's top biopharmaceutical players to drive large-scale manufacturing techniques, particularly for advanced therapies.

The collaborations provide investors with unmatched opportunities to benefit from increasing R&D investment to enhance bioprocessing technology.

Regional Growth Potential | Île-de-France and Lyon

While France is seeing growth in certain regions, the Paris Île-de-France region and Lyon are identified as the primary regions for continued bioprocessing technologies development:

Île-de-France has a series of biopharma champions and a well-developed research infrastructure and universities. The Paris region also has strong government support for biopharma innovation, which makes it a strong site for investment in continuous bioprocessing technologies.

Lyon, the European Biotech Capital, is an effective biomanufacturing center. That there are established biotech companies and research centers, and that it has the support of the local government, makes it an attractive location for investors who want to be part of the tide of innovation in bioprocessing technologies.

Looking to the Future:

France's contribution to shaping the future of Biomanufacturing In the future, the French continuous bioprocessing industry will undergo a radical transformation. With AI, automation, and real-time process monitoring becoming more advanced, France is well positioned to become a leader in the biomanufacturing sector in the world. The combination of cutting-edge technologies, strong R&D infrastructure, and government incentives provides a perfect platform for investors to shape the future of the Continuous Bioprocessing Market.

The increasing demand for biologics, vaccines, and gene therapies and the increasing pressure to reduce costs and timelines for manufacturing will continue to propel the application of continuous bioprocessing. The France Bioproduction Congress 2025 has detailed precisely how crucial this technology will be in the future of biopharmaceutical production.

Investors need to focus on strategic regions like Île-de-France and Lyon, and look for opportunities in AI-driven platforms, bioreactor design, regulatory services, and advanced monitoring technologies to capitalize on the growing momentum of continuous bioprocessing in France.

About Us

Founded in 2015, MarketDigits Consulting & Advisory Pvt Ltd is a leading business research and consulting firm. Our mission is to empower clients by identifying emerging opportunities and driving revenue growth across industries. We specialize in providing comprehensive market insights, advanced technology solutions, and actionable strategies that support operational and strategic decision-making.

With a focus on the full value chain, our expert team delivers high-quality syndicate research reports, proprietary databases, and consulting services to help clients navigate today's competitive and dynamic business environment. At MarketDigits, we use advanced analysis to uncover profitable opportunities, enabling businesses to make smart decisions and achieve sustainable success.

Contact Us:

+1 510-730-3200 | +1 276-206-2055

sales@marketdigits.com

1248 CarMia Way Richmond

VA 23235, United States

This release was published on openPR.